A wide spectrum of pathological conditions may result from the interaction of Aspergillus fumigatus and the immune system of its human host. Allergic bronchopulmonary aspergillosis is one of the most severe A. fumigatus-related diseases due to possible evolution toward pleuropulmonary fibrosis and respiratory failure. Allergic bronchopulmonary aspergillosis occurs almost exclusively in cystic fibrosis or asthmatic patients. An estimated 8%-10% of patients with cystic fibrosis experience this condition. The diagnosis of allergic bronchopulmonary aspergillosis relies on criteria first established in 1977. Progress in the understanding of host-pathogen interactions in A. fumigatus and patients with cystic fibrosis and the ongoing validation of novel laboratory tools concur to update and improve the diagnosis of allergic bronchopulmonary aspergillosis.
air, soil, cereals, fruit, plants, wet and decomposing organic matter.
Airborne Aspergillus spp spores are present indoors and outdoors, with an estimated 10-1000 spores inhaled daily by each human. 4, 5 A growing number of Aspergillus species are recognized as pathogenic for animals and humans; yet A. fumigatus (Figure 1 ) is the most frequently involved in human medicine, with 80%-90% of human aspergilloses being caused by A. fumigatus. 6, 7 Virulence and subversion mechanisms of A. fumigatus are supported by multiple antigenic proteins and toxins which differentially become involved in host interaction depending on immune and environmental factors. Aspergillus fumigatus comprises around 200 antigenic proteins capable of inducing IgG responses and 80 allergenic proteins capable of inducing IgE responses. 8, 9 There is partial overlap between the two categories, with extensive charac- In healthy, immunocompetent hosts, inhaled A. fumigatus spores are eliminated by the mucociliary elevator and alveolar macrophages. 5, [14] [15] [16] The ability of the host's immune system to mount an efficient response is crucial if the first line of defense is overwhelmed. If A. fumigatus manages to persist in the airways and enter the germination process, neutrophils sense and effectively target germ tubes. 17 A. fumigatus spores directly activate bronchial epithelial cells through binding of fungal beta-glucans to cellular dectin-1, resulting in the release of antimicrobial peptides such as pentraxin and mannose-binding lectin, and generation of reactive oxygen species and cytokines. 5, 17 Defective function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein results in reduced chloride and bicarbonate secretion at the apical surface of epithelial cells, leading to more acid and viscous airway surface liquid stagnating in the lumen. 18 Trapped microorganisms are less likely to be eliminated, while the access of soluble antifungal mediators such as pentraxin-3
and mannose-binding lectin is impaired by increased mucus viscosity. 5 The pathophysiological continuum of A. fumigatus-host interaction is mirrored by laboratory and clinical frames of "asymptomatic"
colonization, "benign" IgE sensitization to A. fumigatus, through A. fumigatus-induced cough and asthma, to aspergilloma and invasive aspergilloses. However, the first two stages lack consensus definitions. The growth of A. fumigatus in the airways, also termed "car- 55 In patients with CF, the risk of developing an ABPA is increased in male patients and in cases of associated asthma or atopy, of more severely impaired respiratory function or nutritional status, of Pseudomonas spp carriage in sputum, and of prolonged treatment by azithromycin. 49, 56 In patients with CF, specific challenges need to be overcome during the diagnostic procedure, because of overlapping clinical features between ABPA and CF per se (cough, bronchospasm, intercurrent infections, radiological abnormalities), together with an increased frequency of A. fumigatus colonization and/or sensitization. 52 Moreover, in patients with CF, so-called benign colonization or sensitization by A. fumigatus has been shown to contribute to the deterioration of respiratory function, in pediatric and adult patients, and on native or transplanted lungs. 44, 45, [49] [50] [51] The severity of ABPA resides in the worsening of respiratory and nutritional status. 44 Therapeutic options comprise associations of cor- 
| WHY SHOULD IMMUNOLOGICAL CRITERIA FOR ABPA DIAGNOSIS BE UPD ATED?
A study based on the national registries of 30 countries concluded that ABPA is globally underdiagnosed in patients with CF, with barely 33% reported of the expected ABPA. 59 Notable differences in ABPA diagnosis rates are found even among European countries, with the lowest in Greece (14.5% reported vs expected number of ABPA cases) and the highest end in France (101%). Because, on the one hand, the first-line treatment of ABPA mainly relies on corticosteroids and, on the other hand, the consequences of a lack of ABPA treatment may be irreversible, calls for updating the immunological criteria have been accumulating since the turn of the century. 47, 52, 60 These calls are supported by novel tools with enhanced performance.
We will describe hereafter the issues associated with the current ABPA immunological diagnostic criteria including total serum IgE,
A. fumigatus-specific IgE, and A. fumigatus-specific IgG and precipitins against A. fumigatus. The next paragraph will present the advances in immunological methods, with an emphasis on IgE detection and quantification tools and their potential for improving ABPA diagnosis in patients with CF.
| COMPONENT-RESOLVED DIAGNOSTICS: MOLECULAR ASPECTS OF THE HUMORAL RESPONSE TO ASPERGILLUS FUMIGATUS
Component-resolved diagnostics was coined as a phrase almost 10 years ago, when IgE determination against distinct allergenic proteins (termed "components" or allergens in order to better distinguish individual allergenic proteins from allergenic extracts)
became available for routine diagnostics of most of the airborne, food, and venom allergies. Therefore, A. fumigatus allergenic proteins perform better than extracts for accurate species diagnosis, thanks to their ability to distinguish genuine sensitization from cross-reactivity. 55, 64, 82 Table 2 introduces currently available A. fumigatus allergenic proteins. Current reports on IgG responses to commercially available allergens from A. fumigatus are scarce and address mainly ABPA patients with an asthmatic background. 76 Our team found that IgG4 responses to A. fumigatus allergens did not distinguish between A. fumigatus-sensitized CF patients and active ABPA. 78 A first step toward an integrated IgE and IgG workup might be the use of a single method for head-to-head comparison. This is feasible with current routine autoanalyzers, with very good quantitative performances including interlaboratory comparison. 9, 46, 68, 73, 76, 84, 86 Currently, the lack of commercially available IgG-skewed proteins and the limited number of commercially available allergens do not allow a comprehensive profiling of humoral responses to A. fumigatus proteins in health and disease. 
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